Anti-VEGFR2 antibody therapy for hepatocellular carcinoma

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10766961
APP PUB NO 20170226212A1
SERIAL NO

15501507

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IMCLONE LLCNEW YORK NY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Abada, Paolo B Indianapolis, US 1 0
Chang, Shao-Chun Carmel, US 12 4
Hsu, Yanzhi Basking Ridge, US 1 0
Yang, Ling Bridgewater, US 192 1346

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 8, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 8, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00